Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis

[1] Baden LR(2021)Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med 384 403-16

[2] El Sahly HM(2021)Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 N Engl J Med 384 2187-201

[3] Essink B(2021)Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months N Engl J Med 385 1761-73

[4] Kotloff K(2021)Looking beyond COVID-19 vaccine phase 3 trials Nat Med 27 205-11

[5] Frey S(2021)Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization Vaccine 39 4013-24

[6] Novak R(2022)Effects of previous infection and vaccination on symptomatic omicron infections N Engl J Med 387 21-34

[7] Sadoff J(2021)Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data The Lancet 397 1819-29

[8] Gray G(2022)Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: a nationwide Danish cohort study PLOS Med 19 e1003992-20

[9] Vandebosch A(2022)Analysis of COVID-19 incidence and severity among adults vaccinated with 2-Dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore JAMA Netw Open 5 e2228900-302

[10] Cárdenas V(2022)Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales The Lancet 400 1305-1

[1] Baden LR(2021)Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med 384 403-16

[2] El Sahly HM(2021)Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 N Engl J Med 384 2187-201

[3] Essink B(2021)Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months N Engl J Med 385 1761-73

[4] Kotloff K(2021)Looking beyond COVID-19 vaccine phase 3 trials Nat Med 27 205-11

[5] Frey S(2021)Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization Vaccine 39 4013-24

[6] Novak R(2022)Effects of previous infection and vaccination on symptomatic omicron infections N Engl J Med 387 21-34

[7] Sadoff J(2021)Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data The Lancet 397 1819-29

[8] Gray G(2022)Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: a nationwide Danish cohort study PLOS Med 19 e1003992-20

[9] Vandebosch A(2022)Analysis of COVID-19 incidence and severity among adults vaccinated with 2-Dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore JAMA Netw Open 5 e2228900-302

[10] Cárdenas V(2022)Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales The Lancet 400 1305-1